Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 875403, 10 pages
http://dx.doi.org/10.1155/2013/875403
Review Article

Anti-Inflammatory Dimethylfumarate: A Potential New Therapy for Asthma?

1Pulmonary Cell Research, Department of Biomedicine, University of Basel, Hebelstraße 20, 4031 Basel, Switzerland
2Pneumology, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland

Received 11 December 2012; Revised 7 February 2013; Accepted 7 February 2013

Academic Editor: Gustavo Duarte Pimentel

Copyright © 2013 Petra Seidel and Michael Roth. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. T. Holgate, “Innate and adaptive immune responses in asthma,” Nature Medicine, vol. 18, no. 5, pp. 673–683, 2012. View at Publisher · View at Google Scholar
  2. K. Mullane, “The increasing challenge of discovering asthma drugs,” Biochemical Pharmacology, vol. 82, no. 6, pp. 586–599, 2011. View at Publisher · View at Google Scholar
  3. C. S. Stevenson and M. A. Birrell, “Moving towards a new generation of animal models for asthma and COPD with improved clinical relevance,” Pharmacology and Therapeutics, vol. 130, no. 2, pp. 93–105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. J. Bossley, L. Fleming, A. Gupta et al., “Pediatric severe asthma is characterized by eosinophilia and remodeling without TH2 cytokines,” Journal of Allergy and Clinical Immunology, vol. 129, no. 4, pp. 974–982, 2012. View at Publisher · View at Google Scholar
  5. C. L. Grainge, L. C. K. Lau, J. A. Ward et al., “Effect of bronchoconstriction on airway remodeling in asthma,” The New England Journal of Medicine, vol. 364, no. 21, pp. 2006–2015, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. L. James, J. G. Elliot, R. L. Jones et al., “Airway smooth muscle hypertrophy and hyperplasia in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 10, pp. 1058–1064, 2012. View at Google Scholar
  7. R. O'Reilly, N. Ullmann, S. Irving et al., “Increased airway smooth muscle in preschool wheezers who have asthma at school age,” Journal of Allergy and Clinical Immunology, 2012. View at Publisher · View at Google Scholar
  8. H. L. Huber and K. K. Koessler, “The pathology of bronchial asthma,” Archives of Internal Medicine, vol. 30, pp. 689–760, 1922. View at Google Scholar
  9. D. Ramos-Barbón, R. Fraga-Iriso, N. S. Brienza et al., “T cells localize with proliferating smooth muscle α-actin+ cell compartments in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 3, pp. 317–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. B. N. Lambrecht and H. Hammad, “The airway epithelium in asthma,” Nature Medicine, vol. 18, no. 5, pp. 684–692, 2012. View at Google Scholar
  11. M. U. T. Tran, A. J. Weir, M. V. Fanucchi et al., “Smooth muscle hypertrophy in distal airways of sensitized infant rhesus monkeys exposed to house dust mite allergen,” Clinical and Experimental Allergy, vol. 34, no. 10, pp. 1627–1633, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. C. G. Plopper, S. M. Smiley-Jewell, L. A. Miller et al., “Asthma/allergic airways disease: does postnatal exposure to environmental toxicants promote airway pathobiology?” Toxicologic Pathology, vol. 35, no. 1, pp. 97–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. M. Wahidi and M. Kraft, “Bronchial thermoplasty for severe asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 7, pp. 709–714, 2012. View at Google Scholar
  14. L. J. Janssen, “Airway smooth muscle as a target in asthma and the beneficial effects of bronchial thermoplasty,” Journal of Allergy, vol. 2012, Article ID 593784, 9 pages, 2012. View at Publisher · View at Google Scholar
  15. D. C. Doeing, A. K. Mahajan, S. R. White, E. T. Naureckas, J. A. Krishnan, and D. K. Hogarth, “Safety and feasibility of bronchial thermoplasty in asthma patients with very severe fixed airflow obstruction: a case series,” Journal of Asthma, vol. 50, no. 2, pp. 215–218, 2012. View at Publisher · View at Google Scholar
  16. C. E. Brightling, P. Bradding, F. A. Symon, S. T. Holgate, A. J. Wardlaw, and I. D. Pavord, “Mast-cell infiltration of airway smooth muscle in asthma,” The New England Journal of Medicine, vol. 346, no. 22, pp. 1699–1705, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. D. S. Carnieli, E. Yoshioka, L. F. F. Silva et al., “Inflammation and remodeling in infantile, juvenile, and adult allergic sensitized mice,” Pediatric Pulmonology, vol. 46, no. 7, pp. 650–665, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Black, R. A. Panettieri Jr., A. Banerjee, and P. Berger, “Airway smooth muscle in asthma: just a target for bronchodilation?” Clinics In Chest Medicine, vol. 33, no. 3, pp. 543–558, 2012. View at Google Scholar
  19. A. Stewart, “More muscle in asthma, but where did it come from?” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 10, pp. 1035–1037, 2012. View at Google Scholar
  20. I. M. Adcock, P. A. Ford, P. Bhavsar, T. Ahmad, and K. F. Chung, “Steroid resistance in asthma: mechanisms and treatment options,” Current Allergy and Asthma Reports, vol. 8, no. 2, pp. 171–178, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Bond, C. Spooner, L. Tjosvold, C. Lemière, and B. H. Rowe, “The nature and influence of pharmaceutical industry involvement in asthma trials,” Canadian Respiratory Journal, vol. 19, no. 4, pp. 267–271, 2012. View at Google Scholar
  22. Y. Nakamura, “Developmental current and future therapy for severe asthma,” Inflammation and Allergy Drug Targets, 2012. View at Google Scholar
  23. S. Siddiqui, N. S. Redhu, O. O. Ojo et al., “Emerging airway smooth muscle targets to treat asthma,” Pulmonary Pharmacology & Therapeutics, vol. 5539, no. 12, pp. 1094–10., 2012. View at Publisher · View at Google Scholar
  24. M. Meissner, E. M. Valesky, S. Kippenberger, and R. Kaufmann, “Dimethyl fumarate-only an anti-psoriatic medication?” Journal der Deutschen Dermatologischen Gesellschaft, vol. 10, no. 11, pp. 793–801, 2012. View at Google Scholar
  25. Y. A. Alrashdan, H. Alkhouri, E. Chen et al., “Asthmatic airway smooth muscle CXCL10 production: mitogen-activated protein kinase JNK involvement,” American Journal of Physiology, vol. 302, no. 10, pp. L1118–L1127, 2012. View at Google Scholar
  26. P. Seidel, I. Merfort, J. M. Hughes, B. G. G. Oliver, M. Tamm, and M. Roth, “Dimethylfumarate inhibits NF-κB function at multiple levels to limit airway smooth muscle cell cytokine secretion,” American Journal of Physiology, vol. 297, no. 2, pp. L326–L339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Seidel, K. Hostettler, J. Hughes, M. Tamm, and M. Roth, “Dimethylfumarate inhibits CXCL10 via heme-oxygenase-1 in airway smooth muscle,” European Respiratory Journal, vol. 41, no. 1, pp. 195–202, 2013. View at Google Scholar
  28. P. Seidel, I. Merfort, M. Tamm, and M. Roth, “Inhibition of NF-κB and AP-1 by dimethylfumarate correlates with down-regulated IL-6 secretion and proliferation in human lung fibroblasts,” Swiss Medical Weekly, vol. 140, p. w13132, 2010. View at Google Scholar · View at Scopus
  29. L. Woodman, S. Siddiqui, G. Cruse et al., “Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-β1,” Journal of Immunology, vol. 181, no. 7, pp. 5001–5007, 2008. View at Google Scholar · View at Scopus
  30. P. Berger, D. W. Perng, H. Thabrew et al., “Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells,” Journal of Applied Physiology, vol. 91, no. 3, pp. 1372–1379, 2001. View at Google Scholar · View at Scopus
  31. P. Berger, P. O. Girodet, H. Begueret et al., “Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis,” The FASEB Journal, vol. 17, no. 14, pp. 2139–2141, 2003. View at Google Scholar · View at Scopus
  32. A. L. Lazaar, S. M. Albelda, J. M. Pilewski, B. Brennan, E. Puré, and R. A. Panettieri, “T lymphocytes adhere to airway smooth muscle cells via integrins and CD44 and induce smooth muscle cell DNA synthesis,” Journal of Experimental Medicine, vol. 180, no. 3, pp. 807–816, 1994. View at Publisher · View at Google Scholar · View at Scopus
  33. C. E. Brightling, A. J. Ammit, D. Kaur et al., “The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 10, pp. 1103–1108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. N. G. Carroll, S. Mutavdzic, and A. L. James, “Distribution and degranulation of airway mast cells in normal and asthmatic subjects,” European Respiratory Journal, vol. 19, no. 5, pp. 879–885, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Seidel, M. Roth, Q. Ge, I. Merfort, C. T. S'ng, and A. J. Ammit, “IκBα glutathionylation and reduced histone H3 phosphorylation inhibit eotaxin and RANTES,” European Respiratory Journal, vol. 38, no. 6, pp. 1444–1452, 2011. View at Publisher · View at Google Scholar
  36. P. Seidel, S. Goulet, K. Hostettler, M. Tamm, and M. Roth, “DMF inhibits PDGF-BB induced airway smooth muscle cell proliferation through induction of heme-oxygenase-1,” Respiratory Research, vol. 11, article 145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Van Ly, N. J. King, L. M. Moir, J. K. Burgess, J. L. Black, and B. G. Oliver, “Effects of β2 agonists, corticosteroids, and novel therapies on rhinovirus-induced cytokine release and rhinovirus replication in primary airway fibroblasts,” Journal of Allergy, vol. 2011, Article ID 457169, 11 pages, 2011. View at Publisher · View at Google Scholar
  38. D. J. Lalor, B. Truong, S. Henness et al., “Mechanisms of serum potentiation of GM-CSF production by human airway smooth muscle cells,” American Journal of Physiology, vol. 287, no. 5, pp. L1007–L1016, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. D. L. Clarke, R. L. Clifford, S. Jindarat et al., “TNFα and IFNγ synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-κB, and the transcriptional coactivator CREB-binding protein,” Journal of Biological Chemistry, vol. 285, no. 38, pp. 29101–29110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. E. L. Hardaker, A. M. Bacon, K. Carlson et al., “Regulation of TNF-alpha- and IFN-gamma-induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease,” The FASEB Journal, vol. 18, no. 1, pp. 191–193, 2004. View at Google Scholar · View at Scopus
  41. P. Seidel, H. Alkhouri, D. J. Lalor, J. K. Burgess, C. L. Armour, and J. M. Hughes, “Thiazolidinediones inhibit airway smooth muscle release of the chemokine CXCL10: in vitro comparison with current asthma therapies,” Respiratory Research, vol. 13, p. 90, 2012. View at Google Scholar
  42. T. Trian, G. Benard, H. Begueret et al., “Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma,” Journal of Experimental Medicine, vol. 204, no. 13, pp. 3173–3181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Borger, N. Miglino, M. Baraket, J. L. Black, M. Tamm, and M. Roth, “Impaired translation of CCAAT/enhancer binding protein α mRNA in bronchial smooth muscle cells of asthmatic patients,” Journal of Allergy and Clinical Immunology, vol. 123, no. 3, pp. 639–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. J. M. Coleman, C. Naik, F. Holguin et al., “Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age at onset,” Thorax, vol. 67, pp. 1061–1066, 2012. View at Google Scholar
  45. Y. J. Lee, K. W. Kim, B. S. Choi, M. H. Sohn, and K. E. Kim, “Clinical characteristics of eosinophilic and noneosinophilic asthma in children,” Acta Paediatrica, vol. 102, no. 1, pp. 53–57, 2012. View at Publisher · View at Google Scholar
  46. H. F. Rosenberg, K. D. Dyer, and P. S. Foster, “Eosinophils: changing perspectives in health and disease,” Nature Reviews Immunology, vol. 13, no. 1, pp. 9–22, 2012. View at Publisher · View at Google Scholar
  47. O. Ghaffar, Q. Hamid, P. M. Renzi et al., “Constitutive and cytokine-stimulated expression of eotaxin by human airway smooth muscle cells,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 6, pp. 1933–1942, 1999. View at Google Scholar · View at Scopus
  48. C. Pepe, S. Foley, J. Shannon et al., “Differences in airway remodeling between subjects with severe and moderate asthma,” Journal of Allergy and Clinical Immunology, vol. 116, no. 3, pp. 544–549, 2005. View at Google Scholar
  49. R. Saunders, A. Sutcliffe, L. Woodman et al., “The airway smooth muscle CCR3/CCL11 axis is inhibited by mast cells,” Allergy, vol. 63, no. 9, pp. 1148–1155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. P. J. Chang, P. K. Bhavsar, C. Michaeloudes, N. Khorasani, and K. F. Chung, “Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma,” Journal of Allergy and Clinical Immunology, vol. 130, no. 4, pp. 877–885, 2012. View at Google Scholar
  51. M. Odaka, S. Matsukura, H. Kuga et al., “Differential regulation of chemokine expression by Th1 and Th2 cytokines and mechanisms of eotaxin/CCL-11 expression in human airway smooth muscle cells,” International Archives of Allergy and Immunology, vol. 143, no. 1, pp. 84–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. V. Chan, J. K. Burgess, J. C. Ratoff et al., “Extracellular matrix regulates enhanced eotaxin expression in asthmatic airway smooth muscle cells,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 4, pp. 379–385, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Halwani, J. Al-Abri, M. Beland et al., “CC and CXC chemokines induce airway smooth muscle proliferation and survival,” Journal of Immunology, vol. 186, no. 7, pp. 4156–4163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. T. J. Schall, K. Bacon, K. J. Toy, and D. V. Goeddel, “Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES,” Nature, vol. 347, no. 6294, pp. 669–671, 1990. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Pang, M. Nie, L. Corbett, A. Sutcliffe, and A. J. Knox, “Mast cell β-tryptase selectively cleaves eotaxin and RANTES and abrogates their eosinophil chemotactic activities,” Journal of Immunology, vol. 176, no. 6, pp. 3788–3795, 2006. View at Google Scholar · View at Scopus
  56. N. Berkman, V. L. Krishnan, T. Gilbey et al., “Expression of RANTES mRNA and protein in airways of patients with mild asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 6, pp. 1804–1811, 1996. View at Google Scholar · View at Scopus
  57. U. Oltmanns, R. Issa, M. B. Sukkar, M. John, and K. F. Chung, “Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells,” British Journal of Pharmacology, vol. 139, no. 6, pp. 1228–1234, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. A. J. Ammit, A. L. Lazaar, C. Irani et al., “Tumor necrosis factor-α-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: Modulation by glucocorticoids and β-agonists,” American Journal of Respiratory Cell and Molecular Biology, vol. 26, no. 4, pp. 465–474, 2002. View at Google Scholar · View at Scopus
  59. P. L. Kuo, Y. L. Hsu, M. S. Huang, S. L. Chiang, and Y. C. Ko, “Bronchial epithelium-derived IL-8 and RANTES increased bronchial smooth muscle cell migration and proliferation by Krüppel-like factor 5 in areca nut-mediated airway remodeling,” Toxicological Sciences, vol. 121, no. 1, pp. 177–190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Chhabra, Y. Z. Li, H. Alkhouri et al., “Histamine and tryptase modulate asthmatic airway smooth muscle GM-CSF and RANTES release,” European Respiratory Journal, vol. 29, no. 5, pp. 861–870, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. W. Schweckendiek, “Treatment of psoriasis vulgaris,” Medizinische Monatsschrift, vol. 13, no. 2, pp. 103–104, 1959. View at Google Scholar · View at Scopus
  62. C. Nieboer, D. de Hoop, A. C. Van Loenen, P. N. J. Langendijk, and E. Van Dijk, “Systemic therapy with fumaric acid derivatives: New possibilities in the treatment of psoriasis,” Journal of the American Academy of Dermatology, vol. 20, no. 4, pp. 601–608, 1989. View at Google Scholar · View at Scopus
  63. M. J. Harries, R. J. G. Chalmers, and C. E. M. Griffiths, “Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases,” British Journal of Dermatology, vol. 153, no. 3, pp. 549–551, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Nast, I. Kopp, M. Augustin et al., “German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version),” Archives of Dermatological Research, vol. 299, no. 3, pp. 111–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. M. R. Yazdi and U. Mrowietz, “Fumaric acid esters,” Clinics in Dermatology, vol. 26, no. 5, pp. 522–526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Kappos, R. Gold, D. H. Miller et al., “Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study,” The Lancet, vol. 372, no. 9648, pp. 1463–1472, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. R. J. Fox, D. H. Miller, J. T. Phillips et al., “Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis,” The New England Journal of Medicine, vol. 367, no. 12, pp. 1087–1097, 2012. View at Google Scholar
  68. R. Gold, R. A. Linker, and M. Stangel, “Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action,” Clinical Immunology, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. U. Mrowietz, E. Christophers, and P. Altmeyer, “Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use,” British Journal of Dermatology, vol. 141, no. 3, pp. 424–429, 1999. View at Publisher · View at Google Scholar · View at Scopus
  70. U. Mrowietz, E. Christophers, and P. Altmeyer, “Treatment of psoriasis with fumaric acid esters: Results of a prospective multicentre study,” British Journal of Dermatology, vol. 138, no. 3, pp. 456–460, 1998. View at Publisher · View at Google Scholar · View at Scopus
  71. U. Mrowietz, P. Altmeyer, T. Bieber, M. Röcken, R. E. Schopf, and W. Sterry, “Treatment of psoriasis with fumaric acid esters (Fumaderm),” Journal of the German Society of Dermatology, vol. 5, no. 8, pp. 716–717, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. J. J. Hoefnagel, H. B. Thio, R. Willemze, and J. N. Bouwes Bavinck, “Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis,” British Journal of Dermatology, vol. 149, no. 2, pp. 363–369, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Nieboer, D. de Hoop, P. N. J. Langendijk, A. C. Van Loenen, and J. Gubbels, “Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester,” Dermatologica, vol. 181, no. 1, pp. 33–37, 1990. View at Google Scholar · View at Scopus
  74. N. H. Litjens, J. Burggraaf, E. van Strijen et al., “Pharmacokinetics of oral fumarates in healthy subjects,” British Journal of Clinical Pharmacology, vol. 58, no. 4, pp. 429–432, 2004. View at Google Scholar
  75. M. Vandermeeren, S. Janssens, M. Borgers, and J. Geysen, “Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells,” Biochemical and Biophysical Research Communications, vol. 234, no. 1, pp. 19–23, 1997. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Gesser, C. Johansen, M. K. Rasmussen et al., “Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect,” Journal of Investigative Dermatology, vol. 127, no. 9, pp. 2129–2137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. T. J. Schmidt, M. Ak, and U. Mrowietz, “Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-l-cysteine-Preparation of S-substituted thiosuccinic acid esters,” Bioorganic and Medicinal Chemistry, vol. 15, no. 1, pp. 333–342, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Rostami-Yazdi, B. Clement, T. J. Schmidt, D. Schinor, and U. Mrowietz, “Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action,” The Journal of Investigative Dermatology, vol. 129, no. 1, pp. 231–234, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. K. Reich, D. Thaci, U. Mrowietz, A. Kamps, M. Neureither, and T. Luger, “Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis—a retrospective study (FUTURE),” Journal of the German Society of Dermatology, vol. 7, no. 7, pp. 603–611, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. F. Treumer, K. Zhu, R. Gläser, and U. Mrowietz, “Dimethylfumarate is a potent inducer of apoptosis in human T cells,” Journal of Investigative Dermatology, vol. 121, no. 6, pp. 1383–1388, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Gerdes, K. Shakery, and U. Mrowietz, “Dimethylfumarate inhibits nuclear binding of nuclear factor κB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein β in activated human T cells,” British Journal of Dermatology, vol. 156, no. 5, pp. 838–842, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Höxtermann, C. Nüchel, and P. Altmeyer, “Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis,” Dermatology, vol. 196, no. 2, pp. 223–230, 1998. View at Publisher · View at Google Scholar · View at Scopus
  83. H. J. Bovenschen, A. M. G. Langewouters, and P. C. M. Van De Kerkhof, “Dimethylfumarate for psoriasis: pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study,” American Journal of Clinical Dermatology, vol. 11, no. 5, pp. 343–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Peng, M. Guerau-de-Arellano, V. B. Mehta et al., “Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling,” The Journal of Biological Chemistry, vol. 287, no. 33, pp. 28017–28026, 2012. View at Publisher · View at Google Scholar
  85. T. J. Stoof, J. Flier, S. Sampat, C. Nieboer, C. P. Tensen, and D. M. Boorsma, “The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells,” British Journal of Dermatology, vol. 144, no. 6, pp. 1114–1120, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. B. Gesser, M. K. Rasmussen, L. Raaby et al., “Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression,” Inflammation Research, vol. 60, no. 7, pp. 643–553, 2011. View at Google Scholar
  87. J. C. U. Lehmann, J. J. Listopad, C. U. Rentzsch et al., “Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1,” Journal of Investigative Dermatology, vol. 127, no. 4, pp. 835–845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. R. Loewe, W. Holnthoner, M. Gröger et al., “Dimethylfumarate inhibits TNF-induced nuclear entry of NF-κB/p65 in human endothelial cells,” Journal of Immunology, vol. 168, no. 9, pp. 4781–4787, 2002. View at Google Scholar · View at Scopus
  89. K. Wallbrecht, N. Drick, A. C. Hund, and M. P. Schon, “Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions,” Experimental Dermatology, vol. 20, no. 12, pp. 980–985, 2011. View at Google Scholar
  90. M. Meissner, M. Doll, I. Hrgovic et al., “Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action,” Journal of Investigative Dermatology, vol. 131, no. 6, pp. 1356–1364, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. D. H. Lee, R. Gold, and R. A. Linker, “Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters,” International Journal of Molecular Sciences, vol. 13, no. 9, pp. 11783–11781, 1803. View at Publisher · View at Google Scholar
  92. S. Schimrigk, N. Brune, K. Hellwig et al., “Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study,” European Journal of Neurology, vol. 13, no. 6, pp. 604–610, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. R. Gold, L. Kappos, D. L. Arnold et al., “DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis,” The New England Journal of Medicine, vol. 367, no. 12, pp. 1098–1107, 2012. View at Google Scholar
  94. P. Albrecht, I. Bouchachia, N. Goebels et al., “Effects of dimethyl fumarate on neuroprotection and immunomodulation,” Journal of Neuroinflammation, vol. 9, p. 163, 2012. View at Google Scholar
  95. S. X. Lin, L. Lisi, C. Dello Russo et al., “The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1,” ASN Neuro, vol. 3, no. 2, pp. 75–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. R. H. Scannevin, S. Chollate, M. Y. Jung et al., “Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 341, no. 1, pp. 274–284, 2012. View at Google Scholar
  97. L. A. Hart, V. L. Krishnan, I. M. Adcock, P. J. Barnes, and K. F. Chung, “Activation and localization of transcription factor, nuclear factor-κB, in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 5, pp. 1585–1592, 1998. View at Google Scholar · View at Scopus
  98. M. C. Catley, M. B. Sukkar, K. F. Chung et al., “Validation of the anti-inflammatory properties of small-molecule IκB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle,” Molecular Pharmacology, vol. 70, no. 2, pp. 697–705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. W. R. Henderson, E. Y. Chi, J. L. Teo, C. Nguyen, and M. Kahn, “A small molecule inhibitor of redox-regulated NF-κB and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model,” Journal of Immunology, vol. 169, no. 9, pp. 5294–5299, 2002. View at Google Scholar · View at Scopus
  100. V. Tergaonkar, “NFκB pathway: a good signaling paradigm and therapeutic target,” International Journal of Biochemistry and Cell Biology, vol. 38, no. 10, pp. 1647–1653, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. B. C. Liao, C. W. Hsieh, Y. C. Lin, and B. S. Wung, “The glutaredoxin/glutathione system modulates NF-κB activity by glutathionylation of p65 in cinnamaldehyde-treated endothelial cells,” Toxicological Sciences, vol. 116, no. 1, pp. 151–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. I. S. Kil, S. Y. Kim, and J. W. Park, “Glutathionylation regulates IκB,” Biochemical and Biophysical Research Communications, vol. 373, no. 1, pp. 169–173, 2008. View at Google Scholar
  103. S. A. Cross, D. R. Cook, A. W. Chi et al., “Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection,” The Journal of Immunology, vol. 187, no. 10, pp. 5015–5025, 2011. View at Google Scholar
  104. P. Kirkham and I. Rahman, “Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy,” Pharmacology and Therapeutics, vol. 111, no. 2, pp. 476–494, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. W. A. Wuyts, B. M. Vanaudenaerde, L. J. Dupont, M. G. Demedts, and G. M. Verleden, “N-acetylcysteine reduces chemokine release via inhibition of p38 MAPK in human airway smooth muscle cells,” European Respiratory Journal, vol. 22, no. 1, pp. 43–49, 2003. View at Google Scholar · View at Scopus
  106. S. S. Brar, T. P. Kennedy, A. B. Sturrock et al., “NADPH oxidase promotes NF-κB activation and proliferation in human airway smooth muscle,” American Journal of Physiology, vol. 282, no. 4, pp. L782–L795, 2002. View at Google Scholar · View at Scopus
  107. D. Morse and A. M. K. Choi, “Heme oxygenase-1: from bench to bedside,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 6, pp. 660–670, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Almolki, C. Taillé, G. F. Martin et al., “Heme oxygenase attenuates allergen-induced airway inflammation and hyperreactivity in guinea pigs,” American Journal of Physiology, vol. 287, no. 1, pp. L26–L34, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. L. E. Otterbein, J. K. Kolls, L. L. Mantell, J. L. Cook, J. Alam, and A. M. Choi, “Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury,” The Journal of Clinical Investigation, vol. 103, no. 7, pp. 1047–1054, 1999. View at Publisher · View at Google Scholar
  110. C. Michaeloudes, P. J. Chang, M. Petrou, and K. F. Chung, “Transforming growth factor-β and nuclear factor E2-related factor 2 regulate antioxidant responses in airway smooth muscle cells: role in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 8, pp. 894–903, 2011. View at Publisher · View at Google Scholar